Company intelligence / Profile preview

Follicum

Lund, Sweden

Ownership: Private
Development stage: Phase 2

Overview

FOL‑005 demonstrated promising results in stimulating hair growth in both animal models and early human studies. The injectable formulation completed Phase IIa trials; a topical version entered preclinical development. Diabetes peptide candidates showed increased insulin production in preclinical studies but had not yet advanced to clinical trials at the time of acquisition.

Therapeutic areas: EndocrinologyDermatology
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

FOL-005

Phase 2

Indications: Hair loss

Partnerships

Collaborations with Lund University Diabetes Centre/IRCinternational academic collaborations including with Ralf Paus, a leading researcher in hair biology.

Beyond the preview

Go deeper on Follicum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Follicum.

Explore the full profile